Skinvisible, Inc. (OTCBB: SKVI) National and International Patents Reflect Strong Foundation

Skinvisible, Inc. (OTCBB: SKVI) See StockGuru SKVI Profile

SKVI licenses its patented products in order to generate revenue.

This means patents are crucial.  When you realize how many patents SKVI has — you realize this is an established company with more than patents — established relationships.  More on that tomorrow.

SKVI has six patents approved, including three in the US, and internationally in China, India, Australia, Japan and Korea.

There are a number of U.S. patents pending in addition to PCTs internationally, with many more to be filed. Some of these PCT patents cover up to five products. All patents with Invisicare® are owned by Skinvisible.

  • Six approved patents including the US, India, Australia, China and Japan
  • Nine U.S. patents pending
  • 34 international PCTs

A total of twenty claims have been granted in the South Korean patent which protects Invisicare in the areas of ‘Topical Composition’, ‘Topical Composition Precursor’, and ‘Methods for Manufacturing and Using’.

Pharmaceutical companies are pursuing new or improved revenue streams along with protecting their own intellectual properties. Invisicare® allows companies to sell a patent-protected product that has been revitalized with new benefits, giving them a new story to help combat generic competitors. A prescription dermatology product can generate $100 plus million per year. Some can produce even $200 plus million – and that is why the Company believes the investment into a license with an Invisicare® formulation is a very viable option for these companies. Worldwide patent protection submission for products formulated with Invisicare is ongoing.

Patent Product SKVI Opportunity

Pharmaceutical companies pursue new or improved revenue streams along with protecting their own patented products. New product formulations are expensive and time intensive for companies to undertake. Invisicare® allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. A prescription dermatology product can generate $100+ million per year and many even more – that’s why a pharmaceutical company’s investment in an Invisicare® formulated product is a very viable option.

Skinvisible, Inc. / Skinvisible Pharmaceuticals, Inc.
6320 S. Sandhill Road, Suite 10
Las Vegas, Nevada, 89120 U.S.A.

Phone: 702.433.7154
Fax: 702.433.7192
Email: info@skinvisible.com

Phone: 801.485.7978
Fax: 801.466.6877

About Invisicare: Invisicare is Skinvisible’s patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce irritation and can eliminate some costly manufacturing processes. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com

About Skinvisible Pharmaceuticals, Inc.

Skinvisible is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, license fees, and royalties for the life of the patent. Skinvisible’s value also lies in its ability to continually generate new IP on topical products formulated with Invisicare.

Forward Looking Statements: Certain statements, other than purely historical information, including estimates, projections, statements relating to SKVI business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. SKVI’s ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in other filings with the SEC.

StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030. Disclosure: StockGuru entered into an investor relations consulting and market awareness contract on July 12, 2010.  The company has agreed to pay us five thousand dollars per month in cash for the period of six months, totaling thirty thousand USD. StockGuru was previously compensated 500,000 144 restricted common shares by the company for profile coverage for the period ending January 30, 2010. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program.  This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. To further clarify, we will not be buying or selling shares for the period of July 12, 2010 through January 12, 2011. We hold no shares and will not be receiving further compensation that is share related during this period. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Left Menu Icon
Right Menu Icon